We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+9.04%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$661M
AUM Growth
+$34.1M
Cap. Flow
-$6.85M
Cap. Flow %
-1.04%
Top 10 Hldgs %
25.72%
Holding
101
New
10
Increased
24
Reduced
44
Closed
5

Top Buys

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$12.3M
2
ABMD
Abiomed Inc
ABMD
+$12.2M
3
WBA
Walgreens Boots Alliance
WBA
+$11.2M
4
CVS icon
CVS Health
CVS
+$8.13M
5
BHC icon
Bausch Health
BHC
+$7.75M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$8.33M
2
ALKS icon
Alkermes
ALKS
+$6.79M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.92M
4
HCA icon
HCA Healthcare
HCA
+$5.86M
5
EW icon
Edwards Lifesciences
EW
+$5.84M

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
2 Financials 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STJ
26
DELISTED
St Jude Medical
STJ
$10.8M 1.63%
175,000
-15,000
-8% -$946K
BDX icon
27
Becton Dickinson
BDX
$48.2B
$10.6M 1.61%
70,725
-22,550
-24% -$3.25M
LH icon
28
Labcorp
LH
$25.9B
$10M 1.51%
94,284
– –
CNC icon
29
Centene
CNC
$32.5B
$9.81M 1.48%
298,000
-52,000
-15% -$1.54M
NKTR icon
30
Nektar Therapeutics
NKTR
$2.58B
$9.79M 1.48%
38,733
-7,134
-16% -$1.47M
CAH icon
31
Cardinal Health
CAH
$55.4B
$9.28M 1.4%
104,000
-55,000
-35% -$4.67M
DXCM icon
32
DexCom
DXCM
$32B
$8.6M 1.3%
420,000
+84,000
+25% +$1.75M
HNT
33
DELISTED
HEALTH NET INC
HNT
$8.35M 1.26%
122,000
-28,000
-19% -$1.79M
MDVN
34
DELISTED
MEDIVATION, INC.
MDVN
$7.73M 1.17%
160,000
+46,000
+40% +$1.98M
HALO icon
35
Halozyme
HALO
$12.2B
$7.11M 1.07%
410,000
+238,000
+138% +$3.79M
ENDP
36
DELISTED
Endo International plc
ENDP
$7.1M 1.07%
116,000
+43,000
+59% +$2.61M
VRTX icon
37
Vertex Pharmaceuticals
VRTX
$126B
$7.05M 1.07%
56,000
-49,000
-47% -$5.92M
CEMP
38
DELISTED
Cempra, Inc.
CEMP
$7.04M 1.06%
226,000
-72,000
-24% -$2M
BHC icon
39
Bausch Health
BHC
$2.34B
$7.01M 1.06%
+69,000
New +$7.75M
ITCI
40
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.78M 1.02%
126,000
-39,000
-24% -$1.97M
HCA icon
41
HCA Healthcare
HCA
$89.5B
$6.49M 0.98%
96,000
-84,000
-47% -$5.86M
ESRX
42
DELISTED
Express Scripts Holding Company
ESRX
$6.47M 0.98%
74,000
-22,000
-23% -$1.88M
KERX
43
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$6.23M 0.94%
1,233,000
-330,000
-21% -$1.57M
RVNC
44
DELISTED
Revance Therapeutics, Inc.
RVNC
$5.91M 0.89%
173,000
+25,000
+17% +$867K
JAZZ icon
45
Jazz Pharmaceuticals
JAZZ
$16.7B
$5.9M 0.89%
42,000
-4,700
-10% -$651K
ALNY icon
46
Alnylam Pharmaceuticals
ALNY
$29.3B
$5.84M 0.88%
62,000
-14,000
-18% -$1.3M
RAD
47
DELISTED
Rite Aid Corporation
RAD
$5.32M 0.8%
33,900
+650
+2% +$96.2K
UHS icon
48
Universal Health Services
UHS
$10.5B
$5.26M 0.8%
44,000
-4,900
-10% -$599K
BSX icon
49
Boston Scientific
BSX
$71.5B
$5.05M 0.76%
+274,000
New +$4.91M
CLDX icon
50
Celldex Therapeutics
CLDX
$3.28B
$5.02M 0.76%
21,333
+1,666
+8% +$363K
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2015 Portfolio in Review

As of Q4 2015, Rhenman & Partners Asset Management held 101 positions worth $661M, up 5.4% from $627M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management's Q4 2015 filing shows 10 new, 24 increased, 44 reduced and 5 closed positions. Its largest new stake was Walgreens Boots Alliance: 132,000 shares worth $11.2M. The largest sale was Amgen, an estimated $8.33M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials.

  • Rhenman & Partners Asset Management's largest Q4 2015 buy was Walgreens Boots Alliance: 132,000 shares worth $11.2M.
  • Rhenman & Partners Asset Management added most to Perrigo in Q4 2015, an estimated $12.3M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2015 reduction was Amgen, cutting an estimated $8.33M.
  • Rhenman & Partners Asset Management fully exited Merck in Q4 2015, selling an estimated $4.94M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $661M portfolio in Q4 2015.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 5 in Q4 2015.
  • Rhenman & Partners Asset Management's portfolio value rose 5.4% quarter-over-quarter to $661M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2015, filed 19 Jan 2016.